An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic ...
Akari Therapeutics (AKTX) announced on Thursday the pricing of a private placement financing round, expecting to raise an aggregate of approximately $5.5M in gross proceeds. With these funds, the ...
Akari Therapeutics Plc AKTX shares are ripping higher after the company released preclinical data showing AKTX‑101 produced ...
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 ...
TAMPA, Fla. and LONDON, April 27, 2026 (GLOBE NEWSWIRE)-- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator ...
Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could benefit from its “neuroscience expertise in movement disorders ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a ...
(MENAFN- GlobeNewsWire - Nasdaq) Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari's ...
Approval strengthens Akari’s global intellectual property across all major markets and supports advancement of AKTX-101 and ADC pipeline TAMPA, Fla. and LONDON, April 27, 2026 (GLOBE NEWSWIRE)-- Akari ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results